Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Clinical trial update describing the development of a therapeutic endpoint for pediatric rheumatologic conditions. Recruitment is underway f…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) [NA]
A clinical trial evaluating probiotic treatment for Juvenile Idiopathic Arthritis has completed. The update does not provide trial results.
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: Chronic Non-inflammatory Pains in Rheumatopediatrics
The clinical trial NCT03740347 on chronic non-inflammatory pains in juvenile idiopathic arthritis has been withdrawn.
-
EMA approval · 2026-04-01EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Comparison Of The Effects Of Two Different Exercise Training Based On Internal And External Focus In Children and Adolescents With Rheumatic Diseases [NA]
Completed study comparing two exercise training approaches (internal vs external focus) in children and adolescents with rheumatic diseases,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis [Phase 2, Phase 3]
Long-term safety results from a Phase 2/Phase 3 study of tofacitinib in children with Juvenile Idiopathic Arthritis have been posted.
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Treatment Tapering in JIA With Inactive Disease [Phase 3]
Phase 3 clinical trial update on treatment tapering for Juvenile Idiopathic Arthritis patients in inactive disease; the study has completed.
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Transition to Adulthood Through Coaching and Empowerment [NA]
A completed clinical trial from McMaster University describes a program to support transition to adulthood through coaching and empowerment …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Pfizer is conducting a post-marketing surveillance study in Korea to monitor the safety of tofacitinib (Xeljanz) in pediatric patients with …
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
This clinical trial update describes a regulatory post-marketing surveillance study of Secukinumab (Cosentyx) in Korean patients with hidrad…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Scoliosis and Functional Outcomes in Children With Juvenile Idiopathic Arthritis
This clinical trial, sponsored by Istanbul University, investigates scoliosis and functional outcomes in children with juvenile idiopathic a…
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients [Phase 4]
Phase 4 clinical trial comparing leflunomide plus methotrexate versus methotrexate alone in refractory polyarticular juvenile idiopathic art…
-
EMA approval · 2026-02-16EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH
EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidr…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Transition to Adulthood Through Coaching and Empowerment in Rheumatology [NA]
A completed study evaluating a coaching and empowerment program to help youths with juvenile rheumatic diseases transition to adulthood.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis [Phase 3]
A Phase 3 trial evaluating baricitinib in participants aged 1 year to less than 18 years with juvenile idiopathic arthritis is currently rec…
-
EMA approval · 2026-02-05EMA Authorised: Tocilizumab STADA (previously Tofidence) (tocilizumab) — STADA Arzneimittel AG
EMA authorised STADA's tocilizumab product (Tocilizumab STADA) for rheumatoid arthritis, juvenile idiopathic arthritis, and COVID-19 infecti…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis [Phase 3]
Phase 3 trial comparing methotrexate alone versus methotrexate plus etanercept for minimal/low disease activity in juvenile idiopathic arthr…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Upadacitinib
AbbVie’s expanded access program for Upadacitinib is currently AVAILABLE for patients with Crohn's disease, ulcerative colitis, juvenile idi…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-26EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, an…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) [Phase 3]
A Phase 3 trial (LIMIT-JIA) evaluating strategies to prevent progression in oligoarticular juvenile idiopathic arthritis has completed and p…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Biomarkers in Pediatric Inflammatory Rheumatic Diseases
This clinical trial update reports the completion of a study examining biomarkers in pediatric inflammatory rheumatic diseases, with Juvenil…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Exploring and Measuring the Impact of Steroids in Children and Young People
A recruiting clinical trial investigating how steroids affect health outcomes in children and young people with rheumatic diseases, includin…